E13-04: Radiation therapy for thymic epithelial neoplasms  by Thomas, Charles R.
Copyright © 2007 by the International Association for the Study of Lung Cancer S261
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
MR Imaging
At MR imaging, types A, AB, and B1 thymomas have similar or 
slightly higher signal intensity (SI) than that of muscle on T1-weighted 
images (T1WI) and higher SI than that of muscle on T2-weighted 
images (T2WI) (4, 6, 9-12). At Gd-DTPA enhanced MR imaging, 
homogeneous and moderate enhancement is observed. Most B2 and B3 
thymomas manifest inhomogeneous SI with scattered high-intensity ar-
eas on T2WI, which are corresponded to cystic spaces with or without 
hemorrhage on pathologic examination (6). In a study by Sakai et al 
(6), T2WI indicated that six of 12 invasive thymomas (probably WHO 
type B2 or B3) had lobular internal architecture, with 1- to 2-mm-thick 
low SI lines; for the ﬁve benign thymomas (probably WHO type A, 
AB, B1), this was not, however, the case. Unlike types A, AB, B1, B2, 
and B3 tumors, thymic carcinomas show relatively low SI at both T1- 
and T2WI, appearing as slightly inhomogeneous lesions (12).
FDG- PET
In TET, FDG-PET may be useful in differentiating thymic carcinoma 
from other thymic tumors, thymic hyperplasia, and normal physiologic 
uptake (13). Sasaki et al (7) reported that the standardized uptake value 
(SUV) for thymic carcinoma was signiﬁcantly greater than that for 
invasive or non-invasive thymoma. With an SUV cutoff point of 5.0, 
thymic carcinoma can be differentiated from thymoma with reasonably 
high sensitivity (84.6%), speciﬁcity (92.3%), and accuracy (88.5%). 
There was no statistically signiﬁcant difference in SUV between inva-
sive and non-invasive thymomas.
Conclusions
An awareness of the various imaging ﬁndings of the different types of 
TET, as reﬂected in the WHO histologic classiﬁcation, may be helpful in 
clinical practice for the assessment and treatment of patients with TET.
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Background: Thymoma, thymic carcinoma, and thymic carcinoid 
are derived from the epithelium of the thymus, and are described as 
Thymic epithelial tumors. These neoplasms are well-known for het-
erogeneity in the oncological behaviors, variability in the histological 
appearance, and association with autoimmune diseases represented by 
myasthenia gravis. The main strategy of treatment for thymic epithelial 
tumors is supposed to be surgical resection. There have been many 
reports studying prognostic factors including Masaoka staging system, 
completeness of resection, size of the tumor, the involved organs, and 
association with myasthenia gravis. On the other hand, pathological 
classiﬁcation of thymic epithelial tumors has been confusing and the 
clinical signiﬁcance of histological appearance has been unclear. World 
Health Organization (WHO), however, established a consensus on the 
histological classiﬁcation of the thymic epithelial tumors in 1999.
Aim: We aimed to elucidate the prognostic factors responsible for 
survival, and examined the outcome of surgical treatment based on 272 
patients between 1957 and 2001.
Results: The number of patients according to Masaoka stage is 113 in 
stage I, 64 in stage II, 71 in stage III, 11 in stage IVa, and 13 in stage 
IVb. The number of patients according to World Health Classiﬁcation 
system is 17 in type A, 65 in type AB, 50 in type B1, 89 in type B2, 23 
in type B3 and 28 in type C. 
The proportion of invasive tumor was 11%, 42%, 47%, 69%, 85%, 
and 94%, in type A, AB, B1, B2, B3, and C tumor, respectively. The 
proportion of tumors with involvement of the great vessels was 0%, 
4%, 7%, 17%, 19% and 43% in type A, AB, B1, B2, B3, and C tumor, 
respectively. The proportion of association with myasthenia gravis was 
0%, 7%, 40%, 56%, 10%, and 0% in type A, AB, B1, B2, B3, and C 
tumor, respectively.
According to Masaoka staging system, 10-year survival rate was 99%, 
95%, 91%, 36% and 0% in stage I, II, III, IVa and IVb disease, respec-
tively. According to WHO histological classiﬁcation system, 10-year 
survival rate was 100%, 96%, 97%, 92%, 78% and 68% in type A, AB, 
B1, B2, B3, and C tumor, respectively.
Multivariate analysis was done to determine the independent prognos-
tic factor in thymomas. Masaoka staging system and WHO histologic 
classiﬁcation were the signiﬁcant factors while age, gender, association 
with myasthenia gravis, completeness of resection or involvement of 
the great vessels were not.
Conclusion: Stage and histology are signiﬁcant prognostic factors and 
should be considered when determining the strategy for treatment.
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Pre-operative Radiation Therapy
For locally advanced, large, invasive thymomas that are unresectable or 
marginally resectable, preoperative adjuvant radiation therapy has been 
advocated to render it resectable. Several studies on limited numbers of 
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patients who received preoperative radiotherapy for extensive disease 
note a decrease in tumor burden at the time of surgery with response 
rates as high as 80% and describe a theoretical decrease in the potential 
for tumor seeding during surgery. These series report that preopera-
tive irradiation facilitated total or subtotal resection of the invasive 
thymoma mass by reducing the tumor volume.
Primary Radiation Therapy
Primary radiation therapy alone as the deﬁnitive treatment has been 
advocated in non-surgical candidates or patients with unresectable 
advanced disease (stage III-IV). Arakawa and associates reported on 
twelve patients who presented with unresectable tumors and were 
treated with primary radiation therapy, and seven patients were alive 
from 1 year 8 months to 5 years 1 month. Ciernik and associates 
reported similar outcomes when comparing radiation alone to tumor 
debulking and adjuvant radiation therapy in 31 patients with stage III 
and IV unresectable disease. A 5-year survival of 87% was reported in a 
small group of patients with IVA disease treated with radiation therapy 
alone. Jackson and associates reported an overall survival of 53% at 5 
years and 44% at 10 years for patients with advanced thymoma receiv-
ing radiation following biopsy only or incomplete resection. Urgesi and 
associates reported on the use of radiotherapy alone in 21 patients with 
intrathoracic recurrences of thymoma. The seven-year survival rate of 
70% was similar for those treated with radiation alone and for those 
treated with surgery and adjuvant therapy. However, the retrospective 
nature of these studies, small number of patients, differing amounts of 
clinical disease, and variations in radiation doses and techniques are 
likely confounding variables that may have inﬂuenced the results in the 
literature. 
Currently, the role of preoperative and primary radiation therapy alone 
has generally fallen out of favor. With the improved response rates of 
chemotherapy, most patients with advanced disease will be treated with 
a combined modality approach.
Radiotherapy Techniques, Dose, and Fractionation
In general, radiation therapy uses high energy (>10MV) x-rays gener-
ated by linear accelerators to treat tumors in the thorax. CT scan is 
currently indispensable for adequate radiation treatment planning. 
Clips placed at the time of surgery, either denoting the extent of resec-
tion in completely resected thymomas or outlining regions of residual 
disease, are useful in guiding postoperative radiotherapy. The plan-
ning target volume should include the gross tumor volume, if any, and 
tumor bed with a 1.5- to 2.0-cm margin. Depending on histology and 
surgical ﬁndings, areas of suspicious subclincal disease and regional 
lymphatics are commonly included. Treatment of the entire mediastinal 
nodal basin prophylactically is controversial because the pattern of 
failure within the mediastinal nodes has little similarity to that of lung 
cancer, and a higher normal tissue complication rate can be expected 
if large target volumes are used without any consistent proven beneﬁt 
(60,61,63,64,71,72), although for selected patients with extensive dis-
ease, this extended-ﬁeld approach may be reasonable. Figure 1 shows 
an example of a custom post-operative ﬁeld used for invasive thymon-
mathymoma.
Treatment port arrangements may include a single anterior port, two 
opposed anterior-posterior ports (weighted 2:1 or 3:2), wedged-pair 
techniques, and other more conformal multiple-ﬁeld or intensity modu-
lated radiation therapy (IMRT) arrangements. Given present advanced 
technical capabilities, all patients should be treated daily with two or 
more ﬁelds, preferably with three-dimensional conformal radiotherapy 
to provide dose homogeneity and allow better sparing of adjacent 
normal critical structures. The risks of potential side effects ultimately 
depend on normal tissue tolerance, surrounding critical organs, prior 
treatments, radiation dose, other concurrent therapies, and the general 
health of the patient.
There are various dose and fractionation schemes reported in the litera-
ture. Postoperative total doses of 45 to 55 Gy, in conventional fraction-
ation of 1.8 to 2.0 Gy/day, have been used in most cases of completely 
resected invasive thymomas. While there is no clear dose-response 
relationship because of the paucity of cases and lack of prospective 
randomized studies, for patients with gross residual disease after resec-
tion, or unresectable disease, doses greater than 60 Gy may likely be re-
quired. The M.D. Anderson Cancer Center group noted a 50% in-ﬁeld 
local failure rate, all in stage III and IVa patients who had undergone 
varying degrees of surgical resection receiving less than 60 Gy. 
The local control rates after a complete resection and adjuvant radiation 
therapy have ranged between 65% to 85%.
Thymic carcinoma
Like thymoma, thymic carcinoma also arises in the thymic epithelium 
but with a high propensity for capsular invasion and metastases. How-
ever, low grade tumors are characterized by relatively favorable clinical 
courses with a low incidence of local recurrence and metastasis. Owing 
to the paucity of cases, optimization of therapeutic regimens has yet to 
be completed.
Radiation Therapy
The optimal treatment of thymic carcinoma remains unclear at present, 
owing to the rarity of the disease. Although surgical extirpation remains 
the cornerstone of treatment. 
in most published studies, surgery has often been followed by radiation 
therapy. A prescriptive dose range has yet to be identiﬁed, with most 
studies using 40-70 Gy with standard fractionation scheme (1.8-2.0 Gy/
fraction). Although a survival beneﬁt has not been seen, there is a trend 
toward improved survival and local control. No dose-related advantage 
in mortality has been established, though a relationship between dose 
and local control has been demonstrated. While local control is in-
creased with radiotherapy, survival beneﬁt remains to be demonstrated. 
Thymic Carcinoid Tumors 
Thymic carcinoid tumors, also knownknown, as neuroendocrine tumors 
of the thymus are extremely rare, accounting for less than 5% of all 
Figure 1. Post-operative radiation therapy field covering the surgical tumor 
bed and upper mediastinum. 
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neoplasms of the anterior mediastinum. They often invade locally, com-
monly metastasizing to regional lymph nodes. Distant metastases to 
bone, liver or skin can occur in 30 to 40% of cases and may be seen in 
just over two-thirds of patients within 8 years from initial diagnosis.
Complete surgical resection is the preferred method of treatment, 
although recurrence is common. Despite a lack of evidence, incomplete 
resections followed by radiation (and/or chemotherapy) have been used 
may improve local control without signiﬁcant increased morbidity and 
mortality. However, despite aggressive treatments, most patients do 
poorly; overall 5-year survival according to one report was almost one-
third, with all patients dead after about 9 years. 
Thoracic Radiation Toxicity and Tissue Tolerance 
Radiation therapy to the chest region can affect some of the major 
thoracic organs including the heart, spinal cord, lung, and esophagus. 
Acute symptoms include transient skin reactions, fatigue, cough, 
dysphagia, shortness of breath and dyspnea. Skin atrophy and hyper-
pigmentation, hair loss, telangiectasia, soft tissue fribrosisﬁbrosis may 
occur within the irradiated area, commonly with low energy beam 
therapy. Radiation damage to the ribs and spine appears late and may 
lead to spontaneous, radiation-induced osteoporosis and rib fracture 
within the treated area.
Cardiac irradiation can lead to pericardial disease, valvular and coro-
nary abnormalities, congestive heart failure, arrhythmias, restrictive 
myopathy and even myocardial infarction. Cardiovascular mortality 
can often be avoided by the use of appropriate techniques and avoid-
ance of excessive treatment of the entire heart volume as the risk of 
cardiotoxicity generally is low unless the dose to the entire cardiac 
volume exceeddose to the entire cardiac volume exceeds 40-50 Gy. 
The lung is relatively sensitive to radiation. When a large volume of the 
lung is irradiated, the patient may develop cough and dyspnea resulting 
in radiation pneumonitis, symptoms of which are similar to pneumonia, 
particularly when radiation therapy is delivered in large fraction size 
(>250 cGy) and combined with systemic chemotherapy.
Acute radiation pneumonitis can occur during radiation treatment or 
within a few weeks afterward. Chronic form may occur 4 to 6 months 
after competioncompletion of radiation therapy. Some of the risk 
factors include low pre-treatment performance status, co-morbid lung 
disease, smoking history, poor pulmonary function tests, large volume 
of lung receiving 20 Gy or more, and large fraction size. Radiographic 
differentiation of radiation-induced pulmonary effects from recurrent, 
metastatic disease, or new malignancies can be difﬁcult. Acute radia-
tion changes can be seen as radiographic opacities within the radiation 
treatment boundaries. With time, increased lung density, loss of lung 
volume, and pleural thickening may develop. Although out-of-ﬁeld 
radiation pneumonitis can occur, distinct conﬁnement of these ﬁndings 
within the irradiated volume suggests of radiation-induced changes. 
Most patients with radiation pneumonitis will recovery with early diag-
nosis and proper management with antibiotics and steroids.
Late effects of radiation injury on the mucosa of the aerodigestive tract 
can lead to decreased mucosal pliability, ﬁbrosis and, occasionally, 
chronic ulceration, ﬁstula and necrosis. These are uncommon sequelae 
in the treatment of thymic tumors, but may be seen after high dose of 
radiationof radiation targeted at the esophagus. 
Radiation myelitis is very rare when the dose to the spinal cord is lim-
ited to no more 45 Gy at standard fractionation. Infrequently, radiation-
induced secondary neoplasms may develop in young patients receiving 
radiation therapy. The latency period is often long (>10 years). Radia-
tion-induced sarcomas are more common and well-recognizedwell 
recognized as one of the late complications of radiation therapy. Other 
tumors due to chest radiation therapy include skin, lung, and bone 
tumors. For female patients, chest irradiation can lead to a higher risk 
of developing breast cancer. 
With a number of deciding factors and signiﬁcant variations among 
individual patients, the total dose, number of treatments and ﬁeld size 
must be individualized to maximize the therapeutic effect to provide 
local control and minimize the side effects, patient inconvenience, and 
potential expense of treatment. The risk of late sequelae is generally 
low when proper radiation technique is employed. The ongoing im-
provement in radiation delivery (e.g. 3-D conformal radiation therapy, 
Intensity Modulated Radiation Therapy) will likely decrease the risks 
of radiation complications. 
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The majority of thymic tumors present in an early stage and can be 
cured with primary surgery, with or without post-operative radiation. 
For these tumors, chemotherapy is rarely necessary. However, in the 
management locally-advanced thymic tumors that are either unresect-
able or of borderline resectability, or in the treatment of thymic tumors 
with distant metastases, systemic treatments are a critical component. 
Thymic tumors are relatively sensitive to cytotoxic chemotherapy. 
Because of the rarity of thymic tumors, there is a paucity of random-
ized, phase III data. Phase II studies have shown that chemotherapy 
can shrink tumors and palliate symptoms in patients with advanced 
thymic tumors. The most active single agents for thymic tumors in-
clude cisplatin, ifosfamide, and doxorubicin. Compared to single agent 
chemotherapy, combination chemotherapy leads to improved response 
rates and, in a retrospective series, to improved overall survival[1]. The 
best results for chemotherapy in thymic tumors have been obtained 
with the PAC regimen (cisplatin, doxorubicin, and cyclophosphamide) 
and the ADOC regimen (cisplatin, doxorubicin, vincristine, and cyclo-
phosphamide) with response rates in the metastatic setting of 50% to 
91%[2, 3]. The combination of cisplatin and etoposide also has activity 
in advanced thymic tumors[4]. The addition of ifosfamide to platinum-
based chemotherapy increases toxicity but does not appear to improve 
outcomes in a phase II study[5]. The Eastern Cooperative Oncology 
Group (ECOG) is currently evaluating the combination of carboplatin 
and paclitaxel in advanced thymic tumors. 
Patients who progress following initial chemotherapy may respond 
to re-treatment with the same regimen, particularly if they enjoyed a 
prolonged (greater than 12-month) progression-free interval[6]. Some 
patients respond to steroids[7]. Thymic tumors have been shown to 
possess receptors for somatostatin[8], and an ECOG study of octreotide 
in invasive, recurrent, or metastatic thymoma or thymic carcinoma 
produced a response rate of 30% with a stable disease rate of 37%[9]. 
Induction therapy for locally-advanced thymic tumors may be able to 
convert patients from unresectable to resectable. A phase II study of 
neoadjuvant ADOC in patients with stage III and IV thymomas dem-
onstrated a partial reponse rate of 100%, a 43% complete radiographic 
response, a pathologic complete response at the time of surgery of 31%, 
and a three-year survival of 70%[10]. A phase II study of PAC plus 
prednisone in stage III and IVA thymoma patients produced a partial 
response rate of 67%, a 14% complete radiographic response rate, a 
